Literature DB >> 3922766

Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia.

P R Turner, C Cortese, R Wootton, C Marenah, N E Miller, B Lewis.   

Abstract

Lipoprotein metabolism was studied in eleven patients with Type III hyperlipoproteinaemia, one with normolipidaemic dysbetalipoproteinaemia and eight controls. Apolipoprotein B kinetics in very low density, intermediate density and low density lipoproteins (VLDL, IDL and LDL) was investigated. Fractional catabolic rates (FCRs) of VLDL-apo B and IDL-apo B were lower (P less than 0.005 and P less than 0.001) in the patients: 0.064 +/- 0.018 and 0.059 +/- 0.006 h-1 respectively, (mean +/- SEM), compared with 0.219 +/- 0.035 and 0.243 +/- 0.028 h-1. Synthetic rates (SRs) of IDL-apo B varied widely from 1.5 mg kg-1 day-1 in the subject with normolipidaemic dysbetalipoproteinaemia to 2.8-25.2 mg kg-1 day-1 in Type III. The mean time for conversion of IDL-apo B to LDL-apo B was prolonged, 18.7 h compared with 3.8 h in the controls (P less than 0.001). LDL-apo B pool size and SR were lower in the patients (P less than 0.05 for both). Two patients treated with gemfibrozil showed reduced hyperlipidaemia and decreased SR of VLDL-apo B and IDL-apo B. Dysbetalipoproteinaemia is associated with pronounced impairment of IDL and VLDL-remnant catabolism, lipoprotein levels reflecting an interaction between this defect and SR of these lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922766     DOI: 10.1111/j.1365-2362.1985.tb00152.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

Review 1.  Very low density lipoprotein apolipoprotein B metabolism in humans.

Authors:  T Demant; J Shepherd; C J Packard
Journal:  Klin Wochenschr       Date:  1988-08-15

2.  Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.

Authors:  Esther M M Ooi; Edward D Janus; Susan J Grant; Lucia M T Sinclair; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2010-04-22       Impact factor: 5.922

3.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Authors:  T Demant; D Bedford; C J Packard; J Shepherd
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Abnormal in vivo metabolism of apolipoprotein E4 in humans.

Authors:  R E Gregg; L A Zech; E J Schaefer; D Stark; D Wilson; H B Brewer
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

5.  Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia.

Authors:  K J Williams; K A Petrie; R W Brocia; T L Swenson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

6.  Sheehan's syndrome presenting with type III hyperlipoproteinaemia.

Authors:  D Carr; H M Thornes; A C Rutter; R D Finney; P R Turner
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

7.  Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B.

Authors:  R Ramakrishnan; Y Arad; S Wong; H N Ginsberg
Journal:  J Lipid Res       Date:  1990-06       Impact factor: 5.922

8.  The effect of apolipoprotein E polymorphism on lipid levels in Korean adults.

Authors:  Min-Ho Shin; Hee-Nam Kim; Lian-Hua Cui; Sun-Seog Kweon; Kyeong-Soo Park; Heon Heo; Hae-Sung Nam; Seul-Ki Jeong; Eun-Kyung Chung; Jin-Su Choi
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.